Admission to AIM and First Day of Dealings

Chepstow, South Wales, 9 December 2016 – Creo Medical Group plc (AIM: CREO) (“Creo” or the “Company”), a medical device company focused on the emerging field of surgical endoscopy, is pleased to announce the admission from 8:00 am today of its ordinary shares to trading on AIM, a market operated by the London Stock Exchange plc ("Admission") and the commencement of dealings in its Ordinary Shares under the TIDM "CREO" and with ISIN number GB00BZ1BLL44.

The Admission Document, along with the information required by AIM Rule 26, is available on the Company’s website, www.creomedical.com.

Summary of the Placing

The Placing raised £20 million through a placing of 26,315,800 new Ordinary Shares with institutional and other investors at a placing price of 76 pence per ordinary share.

Creo’s market capitalisation on Admission, based on the Placing Price, is expected to be approximately £61.3 million.

The Company’s significant shareholders, on Admission, include Hargreave Hale Limited, Legal & General Group Plc, Finance Wales and HOYA Group PENTAX Medical and founder, Chris Hancock. 

 

Contacts

Creo Medical
Roseanne Varner
+44 (0)129 160 6005
roseanne.varner@creomedical.com

Cenkos
Ivonne Cantu / Camilla Hume (NOMAD)
Michael Johnson / Russell Kerr (Sales)
+44 (0)207 397 8900

FTI Consulting
Brett Pollard / Mo Noonan
+44 (0)203 727 1000
creo@fticonsulting.com

 

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company’s mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.

The Company’s strategy is to bring the CROMA surgical system to market through a suite of medical instruments which the Company has designed, initially for GI therapeutic endoscopy, an area with high unmet needs. The CROMA system will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.

Immediately following Admission, the Company's issued share capital will consist of 80,711,745 Ordinary Shares with voting rights. This figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.

For more information about Creo Medical please see our website, www.creomedical.com.

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT

 

DISCLAIMERS

General 

This announcement is an advertisement and not a prospectus or admission document and does not constitute an offer to sell or a solicitation of an offer to buy securities in any jurisdiction in which such offer or solicitation is unlawful. Investors should not subscribe for or purchase any transferable securities referred to in this announcement except on the basis of the information in the Admission Document published by the Company (together with its subsidiaries, the "Group") in connection with Admission. Copies of the Admission Document, when published, will be available from the Company’s website, www.creomedical.com and will be available for inspection for a period of 12 months from the date of Admission at the offices of the Company.

This document is only being distributed to and is only directed at (i) persons who are resident in the United Kingdom and who are “qualified investors” within the meaning of Article 2(1)(e) of the Prospectus Directive (“Qualified Investors”) or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2) (a) to (d) of the Order (all such persons in (i), (ii) and (iii) above together being referred to as "relevant persons"). The ordinary shares to be admitted to trading pursuant to Admission (the “Ordinary Shares”) are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such Ordinary Shares will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

In any EEA Member State that has implemented the Prospectus Directive, this communication is only addressed to and is only directed at Qualified Investors in that Member State within the meaning of the Prospectus Directive, and such other persons as this document may be addressed on legal grounds, and no person that is not a relevant person or Qualified Investor may act or rely on this document or any of its contents. The expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU to the extent implemented in any relevant Member State) and includes any relevant implementing measure in the relevant Member State. 

Forward looking statements

This announcement includes forward looking statements relating to the Group's future prospects, developments and strategies that are based on the Directors' current expectations projections, and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements.

Forward looking statements are sometimes identified by the use of terms and phrases such as "believe", "expects", "envisage", "may", "will", "could", "should", "shall", "risk", "intends", "estimates", "aims", "plans", "predicts", "continues", "assumes", "positioned", "targets" or "anticipates" or the negative thereof, variations or comparable expressions, including reference to assumptions. These forward looking statements include all matters that are not historical facts.

They appear in a number of places throughout this announcement and include statements regarding the intentions, beliefs or current expectations of the Directors or the Group relating to the Group's future prospects, developments and strategies and are based on assumptions and estimates and involve risks, uncertainties and other factors that may cause the actual results, financial condition, performance or achievements of the Group or industry results to be materially different from any future results, performance or achievement expressed or implied by such forward looking statements. No assurance can be given that such future results will be achieved. New factors may emerge from time to time that could cause the Group's business not to develop as it expects and it is not possible for the Group to predict all such factors.

Each forward looking statement contained in this announcement speaks only as of the date of the particular statement. The Company, the Directors and the Nominated Adviser expressly disclaim any obligation to update these forward looking statements contained in this announcement to reflect any change in their expectations or any change in future events or developments on which such statements are based unless required to do so by applicable law or regulation, the AIM Rules for Companies or the AIM Rules for Nominated Advisers. No warranty or representation is given by any person as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, projections or forward looking statements contained in this announcement.

Important notice

The contents of this announcement, which have been prepared by and are the sole responsibility of the Company, have been approved by Cenkos Securities plc solely for the purposes of section 21(2)(b) of the Financial Services and Markets Act 2000, as amended.

The distribution of this announcement and other information in connection with Admission may be restricted by law in certain jurisdictions and persons into whose possession this announcement or any document or other information referred to herein should inform themselves about, and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

In particular, this announcement is not for publication or distribution directly or indirectly, in or into, Australia, Canada, Japan, the Republic of South Africa or the United States. The distribution of this announcement in other jurisdictions including (without limitation) Australia, Canada, Japan, the Republic of South Africa, or the United States (or to any resident thereof) may be restricted by law and therefore persons into whose possession this announcement comes should inform themselves of and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities of any company in any jurisdiction. The Ordinary Shares may not, subject to certain exceptions, be offered or sold, directly or indirectly, in, or into, the United States of America, Canada, Australia, Japan or the Republic of South Africa or in any other country, territory or possession where to do so may contravene local securities laws or regulations. The Ordinary Shares have not been nor will be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), or under the securities legislation of any state of the United States, and may not be offered or sold in the United States, except pursuant to an exemption from the registration requirements of the Securities Act. There will be no public offer of securities in the United States.

This announcement (or any part of it) is not to be reproduced, distributed, passed on, or the contents otherwise divulged, directly or indirectly, in or Australia, Canada, Japan, South Africa or the United States of America, or in any country, territory or possession where to do so may contravene local securities laws or regulations.

This announcement does not constitute or form part of, and should not be construed as, an offer for sale or subscription or solicitation of or invitation to make any offer to buy or subscribe for any Ordinary Shares, and neither this announcement nor any part of it shall form the basis of or be relied on in connection with or act as an inducement to enter into any contract or commitment whatsoever.

No reliance may or should be placed by any person for any purposes whatsoever on the information contained in this announcement or on its completeness, accuracy or fairness. The information in this announcement is subject to change. The value of the Ordinary Shares may go down as well as up and investors in the Ordinary Shares may lose some or all of the money invested.

Cenkos Securities plc nor any of its respective directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for/or makes any representation or warranty, express or implied, as to the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from this announcement) or of any other information relating to the Company, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising.

The Company and Cenkos Securities plc expressly disclaim any obligation or undertaking to update, review or revise any forward looking statement contained in this announcement (other than as required by the AIM Rules) whether as a result of new information, future developments or otherwise.

Cenkos Securities plc, which is authorised and regulated by the Financial Conduct Authority (FCA) in the United Kingdom, is acting exclusively for the Company and no one else in connection with the Placing, will not regard any other person (whether or not a recipient of this document) as their respective client in relation to the Placing, and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, nor for providing advice in relation to the Placing, Admission or any other matter referred to in the Admission Document to be published in connection with the Placing.